Something seems very wrong here. Good news after good news after good news, and this keeps sinking. And I get the sense even the resident cheer squad here is a bit nervous as there's been no "wish I had more dry powder!" posts. Absurd.
Understood. But "odds", "likelyhood" and "availability" are tools of speculation. And I'm fine with speculation, as that's really all we have with NVIV right now, as their is no revenue, and only projected earnings after many "ifs" are completed. I'm just saying that a larger pool of analysts arriving at similar valuation estimates would be more inspiring than only two. Hopefully in time Piper and others will join in.
Smuf, that's pretty much what I'm wondering. A price target based on revenue data (real, projected, historical), along with milestones, etc., can be some pretty sound analytics to work with. But without any of that (revenue), it's too easy for "analyst" price targets to be little more than marketing. I agree with Rock that Nap's reasoning sounds sound, but I worry about his target, as it points largely to "patient data" and future milestones. Someone recently maligned me for being "disappointed" and for behaving like an 8-year-old who discovers that Santa's not real. They left out that my disappointment came after the July 8 release stating improvements had been seen in ALL THREE patients. This "3" number was significant, for several months ago, pundits on this board declared unprecedented price spiking when patient 3 showed improvements, as the odds that "coincidental" healing by patients 1 and 2 would be nulled. Didn't happen.
I've tried to dig into the price target of $25, and have only been able to find Wainright and Zach's as the sole analysts behind that price, and have yet to see any detailed info on how they arrived at that target. Ideally, shouldn't we hope a price target is the mean of more than just two analysts? Maybe that's enough, I don't know. But I do know a price target can be based on speculation rather than more calculable data (EPS, Valuation forecasts, etc). Anyone have any insight into this?
I own a good chunk, and have been distracted by some of my other investments, but believe in this company. Hope it turns around. Any chance?
Am I coming across as a fake journalist with bipolarism? I've always felt I was trying to invigorate middle-ground discusion to balance this board from the pumpers and bashers. Guess there's no place for that here. I'll leave you and Envy alone from here on out. Long as i am on this great stock and company, the apetite for make-me-feel-good-about-my-investment propaganda is intolerable. GLTA
by several of the wise-men-on-the-mount here that the third patient was the key to blowing the lid off this stock as a positive report would eliminate the odds that two patients' improvements could be part of the 5% who see some level of recovery post accident without any treatment.. That report came out. Share price dropped. Confer calls it "normal" pullback. Not sure if anything but crazy revenue reports will move tho stock up at this point, and we're probably years away from that, if ever.
Correct. That's all it is. Too many reading too much into this spike (which followed a dive), especially the opportunistic Tonto.
"Ever since we up-listed to the NASDAQ, the price of this stock has been steadily going up - week after week after week."
I believe day after uplist stock hit $16.85.
PM's jump-the-shark moment for me was his absurd "hour-and-sixteen-minute" "interview" with Jordan. You had to be drunk or high to buy that piece, but nearly everyone here did. Nice to see this board is maturing and focusing on facts and reality rather than dreams and illusions (or delusions).
Good for you to question "Realityville." Great stock to own, and have been here over 3 years, and have witnessed the best and worst of times. You'll find this board has unabashed pumper/cheerleaders and low-life bashers. There are some pragmatist/realists here, but they are either quiet or few. That said, most projections here are grossly over inflated and not based in any metric beyond wishful thinking. I dont see $40 by years end, but hope to be proven very wrong.
I've been so consumed with the action over at NVIV, I've neglected to follow SSYS, for which I hold a moderate position. Anyone with knowledge care to share projected pps for down the road? Many thanks.
Confer's been around long before Perrin came, but he is a valuable resource here.
Great article. Thanks for sharing. To combat this, perhaps NVIV could do what CEO of Biolase did a couple of years ago...call it out via dividends paid to long-term shareholders. He said this back in 2013...
"It is widely known in the stock market that shorting and illegal naked shorting are often used to manipulate stocks and cause unjust enrichment of ruthless speculators. I advise management of all small cap companies that are subject to attacks from naked short sellers to uncover such illegal activities and protect their shareholders by issuing stock dividends on a quarterly, or even monthly, basis. This practice results in an automatic audit of issued and outstanding shares and help to keep away naked short sellers."
Agreed, NFL, that we're undervalued. Curious what it will take to re-establish fair value. The only thing to bear in mind, that while NVIV did hit $6 during the Frank Reynolds Traveling Circus days, I'm not sure $6 was an indicator of value, rather than merely a hype-driven price spike.